Biotechnology News and Research

RSS

Scientists create nanoscale coating to eradicate methicillin resistant bacteria

Building on an enzyme found in nature, researchers at Rensselaer Polytechnic Institute have created a nanoscale coating for surgical equipment, hospital walls, and other surfaces which safely eradicates methicillin resistant Staphylococcus aureus (MRSA), the bacteria responsible for antibiotic resistant infections.

17 Aug 2010

Key scientific work in Cardio3 BioSciences' C-Cure stem cell heart failure treatment published in JACC

Cardio3 BioSciences, a leading Belgian biotechnology company specialising in regenerative therapies for the treatment of cardiovascular disease, today announces that the key scientific work underlying its lead pharmaceutical product C-Cure(R), a revolutionary stem cell treatment for heart failure, has been published in the Journal of the American College of Cardiology (JACC). The findings were described as "landmark work" in the accompanying editorial in today's publication.

17 Aug 2010

Cytomedix second quarter 2010 revenue increases 102% to $1.15 million

Cytomedix, Inc. (the "Company"), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced financial results for the three and six months ended June 30, 2010.

17 Aug 2010

Enrollment open in Phase I clinical study of Morphotek's MORAb-028 for advanced melanoma

Morphotek, Inc., a subsidiary of Eisai Inc., announced today that the John Wayne Cancer Institute in Santa Monica, California has opened enrollment in a Phase I clinical study with MORAb-028 in patients with advanced melanoma.

16 Aug 2010

Green Cross receives KFDA approval to manufacture, market i.v. peramivir: BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc. announced that its partner, Green Cross Corporation has received marketing and manufacturing approval from KFDA for intravenous peramivir to treat patients with influenza A & B viruses, including pandemic H1N1 and avian influenza. Green Cross Corp. intends to launch peramivir under the commercial name PeramiFlu in South Korea.

16 Aug 2010

Adeona reports $979,782 net income for second-quarter 2010 vs. $879,550 net loss for same period in 2009

Adeona Pharmaceuticals, Inc. announced its second quarter 2010 financial results and recent achievements.

16 Aug 2010

Scientists use PCT technique to understand physical effects of compression on macromolecules

Scientists are turning to a decades-old technique to better understand the physical effects of compression on macromolecules and how it might impact their research in proteomics, mass spectrometry, protein extraction, and tissue investigations, reports Genetic Engineering & Biotechnology News.

16 Aug 2010

Survey: Majority of U.S. pharmaceutical companies develop drugs for mental illness

Pharmaceutical research and biotechnology companies in New Jersey, California, New York and North Carolina are responsible for 192 of the 313 medicines in development today to treat mental illnesses, a new survey shows.

16 Aug 2010

Scientists replace human gene to preserve photoreceptor function in retinal degeneration

The easy accessibility of the eye and the established link between specific genetic defects and ocular disorders offer hope for using gene therapy to provide long-term therapeutic benefit. Two reports in the current issue of Human Gene Therapy, a peer-reviewed journal published by Mary Ann Liebert, Inc., describe the effective replacement of a human gene to preserve photoreceptor function in a mouse model of severe retinal degeneration. The articles are available free online.

16 Aug 2010

Nymox second-quarter net loss increases to $1.75 million

Nymox Pharmaceutical Corporation announced today its financial results for the second quarter of 2010. Nymox reported a net loss of $1,745,798, or $0.05 per share for the quarter and $3,015,348, or $0.10 per share for the six months ending June 30, 2010, compared to $1,220,152, or $0.04 per share for the quarter and $2,224,411, or $0.07 per share for the six months ending June 30, 2009. Net losses include stock compensation charges for the quarter of $245,245 in 2010 and $248,886 in 2009 and for the six months ending June 30 of $440,465 in 2010 and $558,536 in 2009.

16 Aug 2010

AIBioTech receives new government contract worth $21 million

American International Biotechnology Services (AIBioTech), a division of Bostwick Laboratories, Richmond, VA, today announced that it is one of four contractors awarded a new government contract valued at approximately $21 million. AIBioTech provides integrated research and development sciences and clinical testing services to physicians and life sciences investigators in biotechnology and pharmaceutical companies, academic institutions, and government agencies. The new contract will be funded in phases, with the first AIBioTech phase valued at nearly $3 million. AIBioTech has assembled a consortium of seven leading technology and biotechnology companies who are poised to meet all of the anticipated scientific objectives.

16 Aug 2010

Dyadic second-quarter 2010 total revenue decreases to $2.2 million

Dyadic International, Inc., a global biotechnology company focused on the discovery, development, manufacture and sale of specialty enzyme products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries, today announced financial results for the second quarter ended June 30, 2010.

13 Aug 2010

MDS Nordion extends cobalt-60 long-term supply agreement with Ontario Power Generation

MDS Nordion, a leading provider of products and services to the global health science market, today announced it has extended its existing agreement with Ontario Power Generation Inc., the Canadian-based electricity generation company, until 2020 for the secure supply of cobalt-60 used in gamma sterilization technologies around the world.

13 Aug 2010

Neurologix second-quarter net loss increases to $4.5 million

Neurologix, Inc., a biotechnology company developing innovative gene therapies for the brain and central nervous system, today reported its financial results for the three and six months ended June 30, 2010.

13 Aug 2010

Epitomics spins-out Apexigen to develop and commercialize humanized rabbit monoclonal antibodies

Epitomics, Inc. today announced that it has spun-out to its shareholders a new biotechnology company called Apexigen, Inc., which will focus on the development and commercialization of humanized monoclonal antibodies for treatment of cancer and immuno-disorders.

13 Aug 2010

Kibow to support KDAE week for educating policymakers about kidney disease

Kibow Biotech would like to show its support for Kidney Disease Awareness and Education (KDAE) Week 2010, organized by American Nephrology Nurses' Association (ANNA). Kidney Disease Awareness and Education Week is a week dedicated to educating policymakers and their staff members about the needs of patients suffering from or at risk for end stage renal disease (ESRD).

13 Aug 2010

NovaBay second-quarter net loss increases to $1.2 million

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, today reported second quarter financial results and highlighted the clinical progress of its in-house programs.

13 Aug 2010

Akela reports $0.1M net income for second-quarter 2010 vs. $1.1M net loss for same period in 2009

Akela Pharma, Inc., a leader in the development of therapeutics for the treatment of pain, and the company's wholly owned subsidiary, PharmaForm, today announced its financial results for the three and six months ended June 30, 2010.

13 Aug 2010

Astex and MMRC commence Phase II clinical trial of AT7519 CDK inhibitor in multiple myeloma

Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, and the Multiple Myeloma Research Consortium announced today the initiation of a Phase II clinical trial of the cyclin-dependent kinase inhibitor, AT7519, to treat patients with relapsed or refractory multiple myeloma, an incurable blood cancer. The trial is designed to investigate both single agent and combination activity of AT7519 with bortezomib (Velcade®).

13 Aug 2010

Transgenomic second-quarter net loss increases to $1.1 million

Transgenomic, Inc. today reported financial results for the three and six months ended June 30, 2010, and provided a business update.

13 Aug 2010

Biotechnology News and Research

Scientists create nanoscale coating to eradicate methicillin resistant bacteria

Key scientific work in Cardio3 BioSciences' C-Cure stem cell heart failure treatment published in JACC

Cytomedix second quarter 2010 revenue increases 102% to $1.15 million

Enrollment open in Phase I clinical study of Morphotek's MORAb-028 for advanced melanoma

Green Cross receives KFDA approval to manufacture, market i.v. peramivir: BioCryst Pharmaceuticals

Adeona reports $979,782 net income for second-quarter 2010 vs. $879,550 net loss for same period in 2009

Scientists use PCT technique to understand physical effects of compression on macromolecules

Survey: Majority of U.S. pharmaceutical companies develop drugs for mental illness

Scientists replace human gene to preserve photoreceptor function in retinal degeneration

Nymox second-quarter net loss increases to $1.75 million

AIBioTech receives new government contract worth $21 million

Dyadic second-quarter 2010 total revenue decreases to $2.2 million

MDS Nordion extends cobalt-60 long-term supply agreement with Ontario Power Generation

Neurologix second-quarter net loss increases to $4.5 million

Epitomics spins-out Apexigen to develop and commercialize humanized rabbit monoclonal antibodies

Kibow to support KDAE week for educating policymakers about kidney disease

NovaBay second-quarter net loss increases to $1.2 million

Akela reports $0.1M net income for second-quarter 2010 vs. $1.1M net loss for same period in 2009

Astex and MMRC commence Phase II clinical trial of AT7519 CDK inhibitor in multiple myeloma

Transgenomic second-quarter net loss increases to $1.1 million

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News